摘要
目的:探讨用恩替卡韦治疗慢性乙肝患者过程中血清乙肝大蛋白(HBV-LHBs)的变化与抗病毒疗效的关系。方法:分别检测30例用恩替卡韦抗病毒治疗的慢性乙型肝炎患者在0个月、6个月、12个月、18个月、24个月时的LHBs、HBV DNA、HBeAg的水平。结果:30例乙肝患者在入组时的LHBs阳性检出率90.00%(27/30)与HBV-DNA的阳性检出率100.00%(30/30)比较差异无统计学意义(χ2=3.16,P>0.05),LHBs的含量(OD值)与HBV-DNA拷贝数的对数呈正相关性(r=0.885)。LHBs的阳性检出率与HBeAg的阳性检出率(73.33%)比较差异有统计学意义(χ2=2.78,P>0.05)。恩替卡韦组0个月、6个月、12个月、18个月、24个月抗病毒治疗无效风险预测值分别为0.28、036、0.46、0.57、0.67。结论:血清LHBs与HBV-DNA有较好的一致性,可作为一个新的判断病毒复制的指标。抗病毒治疗过程LHBs阳性持续时间越长,预示着抗病毒治疗无效的风险性越大。
Objective：To review the clinical value of hepatitis B virus large surface protein（LHBs） in the therapeutic observation of entecavir on chronic hepatitis B. Methods：The levels of serum LHBs,HBV DNA, HBeAg of 30 chronic hepatitis B with anti - viral of entecavir were determined at the time of 0, 6, 12, 18, 24 months. Results：There was no statistically significant different between the positive rate of LHBs（90. 00% ） and HBV DNA （ 100.00% ） （χ^2 = 3.16, P 〉 0. 05 ）. LHBs levels （ Optical Density） were correlated with the logarithm of HBV DNA copies （r = 0. 885）. There was s no significant different between the positive rate of HBeAg（73.33% ） and LHBs（χ^2 = 2.78, P 〉 0.05）. Conclusion：The serum LHBs has a good consistency with HBV DNA. It can be used as a new indicator of viral replication. The longer of the LHBs positive duration, the higher risk of invalid anti - virus treatment.
出处
《中国卫生检验杂志》
CAS
2009年第10期2334-2336,共3页
Chinese Journal of Health Laboratory Technology
基金
杭州市医药卫生科技计划项目(2008B053)
关键词
恩替卡韦
慢性乙型肝炎
抗病毒治疗
乙肝病毒表面大蛋白
反式激活
Entecavir
Chronic hepatitis B
Anti- virus treatment
Hepatitis B virus large surface protein
Trans- activation
